[Seite 85↓]

8. Literaturverzeichnis

1. Abagyan, R.A., Totrov, M., Kutznetsov, D.N. (1994): ICM – a new method for protein moedeling and design. Applications to docking and structure prediction from the distorted native conformation, J. Comp. Phys. 151: 402-421

2. Ballou, B., Fisher, G.W., Waggoner, A.S., Farkas, D.L., Reiland, J.M., Jaffe, R., Mujumdar, R.B., Mujumdar, S.R., Hakala, T.R. (1995): Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies, Cancer Immunol. Immunother . 41: 257-263

3. Ballou, B., Fisher, G.W., Hakala, T.R., Farkas, D.L. (1997): Tumor detection and visualization using cyanine fluorochrome-labeled antibodies, Biotechnol. Prog. 13: 649-658

4. Beaudet, A., Nouel, D., Stroh, T., Vandenbulcke, F., Dal-Farra, C., Vincent, J.-P. (1998): Fluorescent ligands for studying neuropeptide receptors by confocal microscopy, Braz. J. Med. Biol. Res. 31: 1479-1489

5. Becker, A., Riefke, B., Ebert, B., Sukowski, U., Rinneberg, H., Semmler, W., Licha, K. (2000): Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin, Photochem. Photobiol . 72: 234-241

6. Becker, A., Hessenius, C., Licha, K., Ebert, B., Sukowski, U., Semmler, W., Wiedenmann B., Grötzinger, C. (2001): Receptor-targeted optical imaging of tumors with near-infared fluorsescent ligands, Nat. Biotechnol. 19: 327-331

7. Blaber, M., Zhang, X., Matthews, B.W. (1993): Structural basis of amino acid α helix propensity, Science 260: 1637-1639

8. Bodanszky, M., Klausner, Y.S., Said, S. (1973): Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of the vasocative intestinal peptide, Proc. Nat. Acad. Sci. USA 70: 382-384


[Seite 86↓]

9. Bolin, D.R., Michalewsky, J., Wasserman, M.A., O`Donnell, M. (1995): Design and development of a vasoactive intestinal peptide anlog as a novel therapeutic for bronchial asthma, Biopolymers 37 : 57-66

10. Bongers J., Heimer E.P., Lambros T., Pan Y.C., Campbell R.M., Felix A.M. (1992): Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor, Int. J. Pept. Protein. Res. 39: 364-74

11. Carter, P.H., Resto-Ruiz, S., Washington, G.C., Ethridge, S., Palini, A., Vogt, R., Waxdal, M., Fleisher, T., Noguchi, P.D., Marti, G.E. (1992): Flow cytometric analysis of whole blood lysis, three anticoagulants and five cell preparations, Cytometry 13: 68-74

12. Chadker, S., Rattan, S. (1993): The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: Functional and binding studies an opossum internal anal sphincter smooth muscle, J. Pharmcol. Exp. Therap. 266: 392-399

13. Cheng, Y.C., Prusoff, W. (1973): Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 % inhibition (IC50) of an enzymatic reaction, Biochem. Pharmacol. 22: 3099-3108

14. Couvineau, A., Amiranoff, B., Vauclin-Jacques, N., Laburthe, M. (1984): Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: effect of nine partial sequences, Biochem. Biophys. Res. Commun. 121, 493-498

15. Couvineau, A., Rousset, M., Laburthe, M. (1985) : Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line HT-29, Biochem. 231: 139-143

16. Couvineau, A., Fabre, C., Gaudin, P., Maoret, J.J., Laburthe, M. (1996a): Mutagenesis of N-glycosylation sites in the human VIP 1 receptor, Ann. N Y Acad. Sci. 805: 558-562


[Seite 87↓]

17. Couvineau, A., Rouyer-Fessard, C., Maoret, J.J., Gaudin, P., Nicole, P., Laburthe, M. (1996): Vasoactive intestinal peptide (VIP)1 receptor, J. Biol. Chem. 271: 12795-12800

18. Di Cera, E. (1998): Site-specific thermodynamics: Understanding cooperativity in molecular recognition, Chem. Rev. 98: 1563-1591

19 . Dickinson, T., Fleetwood-Walker, S.M. (1999) VIP and PACAP; very important in pain? TiPS 20: 324-329

20. Dickson, E.F., Holmes, H., Jori, G., Kennedy, J.C., Nadeau, P., Pottier, R.H., Rossi, F., Russell, D.A., Weagle, G.E. (1995): On the source of the oscillations observed during in vivo zinc phthalocyanine fluorescence pharmacokinetic measurements in mice. , Photochem. Photobiol 61: 506-509

21. Domschke, S., Domschke, W., Bloom, S.R., Mitznegg, P., Mitchell, S.J., Lux, G., Strunz, U. (1978): Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects, Gut 19: 1049-1053

22. Dougherty, T.J., Gomer, C.J., Henderson, B.W., Jori, G., Kessel, D., Korblik, M., Moan, J., Peng, Q. (1998): Review: Photodynamic therapy, J. Nat. Cancer Inst. 17: 889-905

23. Follis, S., Westermann, P., Braichotte, D., Pelegrin, A., Wagnieres, G., van den Bergh, H., Mach, J.P. (1994): Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice, Cancer Res. 15: 2643-2649

24. Frank, R. (1992): Spot synthesis: an easy technique for the positionally adressable, parallel chemical synthesis on a membrane support, Tetrahedron 48: 9217-9232

25. Frishman, D., Argos, P. (1996): Incorporation of non-local interactions in protein secondary structure predicition from the amino acid sequence, Protein Eng. 9: 133-142

26. Fry, D.C., Madison, V. S., Bolin, D.R., Greeley, D.N., Toome, V., Wegrzynski, B.B. (1989): Solution structure of an analogue of vasoactive intestinal peptide as determined by two-dimensional NMR and circular dichroism spectroscopies and constrained molecular dynamics, Biochem. 28: 2399-2409


[Seite 88↓]

27. Gaudin, P., Couvineau, A., Maoret, J.J., Rouyer-Fessard, C., Laburthe, M. (1996): Establishment of a CHO cell clone stably expressing the recombinant human VIP-1 receptor , Ann. N Y Acad. Sci. 805: 570-573

28. Gaudin, P., Maoret, J.J., Couvineau, a., Rouyer-Fessard, C., Laburthe, M. (1998): Constitutive activation of the human vasoactive intestinal peptide 1 receptor, a member of the new class II family of G protein-coupled receptor, J. Biol. Chem. 273: 4990-4996

29. Goldsmith, S.J. (1997): Receptor imaging: competitive or complementary to antibody imaging?, Semin. Nucl. Med. 27: 85-93

30. Goossens, J.-F., Cotelle, P., Chavatte, P., Hénichart, J.-P. (1996): NMR Study of five N-terminal peptide fragments of the vasoactive intestinal peptide : Crucial role of aromatic residues, Peptide Research 9: 322-326

31. Gourlet, P., Vandermeers, A., Vandermeers-Piret, M.-C., De Neef, P., Waelbroek, M., Robberecht, P. (1996) : Effect of introduction of an Arginine16 in VIP, PACAP and secretin on ligand affinity for the receptors, Biochim. Biophys. Acta 1314: 267-273

32. Gourlet, P., Vandermeers, A., Vertongen, P., Rathe, J., De Neef, P., Cnudde, J., Waelbroek, M., Robberecht, P. (1997): Development of high affinity selective VIP1 receptor agonists, Peptides 18: 1539-1545

33. Gozes, I., Fridkin, M., Hill, J.M., Brennemann, D.E. (1999a): Pharmaceutical VIP: Prospects and problems, Curr. Med. Chem. 6: 1019-1034

34. Gozes, I., Perl, O., Giladi, E., Davidson, A., Ashur-Fabian, O., Rubintraut, S., Fridkin, M. (1999b): Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design, Proc. Natl. Acad. Sci. USA 96: 4143-4148


[Seite 89↓]

35. Harmar, A.J., Arimura, A., Gozes, I., Journot, L., Laburthe, M., Pisegna, J.R., Rawlings, S.R., Robberecht, P., Said, S.I., Spreedharan, S.P., Wank, S.A., Waschek, J.A. (1998): International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and adenylate cyclase-activating polypeptide, Pharmacological Rev. 50: 265-270

36. Heppeler, A., Froidevaux, S., Eberle, A.N., Maecke, H.R. (2000): Receptor targeting for tumor localisation and therapy with radiopeptides, Curr. Med. Chem. 7: 971-994

37. Hessenius, C., Bäder, M., Böhmig, M., Faiss, S., Reubi, J.C., Meinhold, H,. Wiedenmann, B. (2000): Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumors, Eur. J. Nucl. Med. 27, 1684-1693

38. Hofstee B.H.J. (1952): On the evaluation of the constants Vm and Km in enzyme reactions, Science 116: 329-331

39. Holtmann, M.H., Hadac, E.M., Miller, L.J. (1995): Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors, J. Biol. Chem. 270: 14394-14398

40. Holst, B., Zoffmann, S., Elling, C.E., Hjorth, S.A., Schwartz, T.W. (1998): Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin N1 receptor, Mol. Pharmacol. 53: 166-175

41. Ishihara, T., Shigemoto, R., Mori, K., Takahashi, K., Nagata, S. (1992): Functional expression and tissue distribution of a novel receptor for vasoactive intestinal peptide, Neuron 8: 811-819

42. Jensen, R.T., Gibril, F., Termanini, B. (1997): Definition of the role of somatotastin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization, Yale J. Biol. Med. 70: 481-500

43. Keltz, T.N., Straus, E., Yalow, R.S. (1980): Degradation of vasoactive intestinal polypeptide by tissue homogenates, Biochem. Biophys. Res. Commun. 92: 669-674


[Seite 90↓]

44. Kendall, J.M., Badminton, M.N. (1998): Aequorea victoria bioluminescence moves into an exciting new era, TIBTECH 16: 216-224

45. Kramer, A., Keitel, T., Winkler, K., Stöcklein, W., Höhne, W., Schneider-Mergener, J. (1997): Molecular basis for the binding promiscuity of an Anti-p24 (HIV-1) monoclonal antibody, Cell 91: 799-809

46. Laburthe, M., Rousset, M., Boissard, C., Chevalier, G., Zweibaum, A., Rosselin, G. (1978): Vasoactive intestinal peptide : A potent stimulator of adenosine 3´,5´-cyclic monophosphate accumulation in gut carcinoma cell lines in culture, Proc. Natl. Acad. Sci. USA 75: 2772-2775

47. Laburthe, M., Couvineau, A., Gaudin, P., Maoret, J.J., Royer-Fessard, C., Nicole, P. (1996): Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1 and other members of their new family of G protein linked receptors: structure-function relationship with special reference to the human VIP-1 receptor, Ann. N. Y. Acad. Sci. 805: 94-109

48. Lelièvre, V., Pineau, N., Du, J., Wen, C.-H., Nguyen, T., Janet, T., Muller, J.-M., Waschek, J.A. (1998): Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation, J. Biol. Chem. 273 : 19685-19690

49. Licha, K., Bhargava, S., Rheinländer, C., Becker, A., Schneider-Mergener, J., Volkmer-Engert, R. (2000a): Highly parallel nano-synthesis of cleavable peptide-dye conjugates on cellulose membranes, Tetrahedron Letters 41: 1711-1715

50. Licha, K., Riefke, B., Ntziachristos, V., Becker, A., Chance, B., Semmler W. (2000b): Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization, Photochem. Photobiol. 72: 392-398

51. Licha, K., Becker, A., Hessenius, C., Bauer, M., Henklein, P., Wiedenmann, B., Semmler, W. (2001): Synthesis, characterization and biological properties of cyanine-labeled somatostatin analouges as receptor-targeted fluorescent probes, Bioconjug. Chem. 12: 44-50


[Seite 91↓]

52. Lins, L., Couvineau, A., Rouer-Fessard, C., Nicole, P., Maoret, J.J., Benhamed, M., Brasseur, R., Thomas, A., Laburthe, M. (2001): The human VPAC1 receptor; 3D model and mutagenesis of the N-terminal domain, J. Biol. Chem. 30: 10153-10160

53. Luis, J., Muller, J.-M., Abadie, B., Martin, J.-M., Marvaldi, J., Pichon, J. (1986): Cycle of vasoactive intestinal peptide and its binding site in a human adenocarcinoma cell line (HT29), Eur. J. Biochem. 156: 631-636

54. Lutz, E.M., Sheward, W.J., West, K.M., Morrow, J.A., Fink, G., Harmar, A.J. (1993): The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide, FEBS Lett. 334: 3-8

55. Mahmood, U., Tung, C.-H., Bogdanov, A., Weissleder, R. (1999): Near-infrared optical imaging of protease activity for tumor detection, Radiology 213: 866-870

56. Maruno, K., Absood, A., Said, S. (1998): Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo, Proc. Natl. Acad. Sci . 95: 14373-14378

57. Muller, J.-M., El Battari, A., Ah-Kye, E., Luis, J., Ducret, F., Pichon, J. (1985): Internalization of the vasoactive intestinal peptide (VIP) in a human adenocarcinoma cell line (HT29), Eur. J. Biochem. 152: 107-114

58. Nabuchi Y., Fujiwara E., Kuboniwa H., Asoh Y., Ushio H. (1997): The stability and degradation pathway of recombinant human parathyroid hormone: deamidation of asparaginyl residue and peptide bond cleavage at aspartyl and asparaginyl residues,Pharm. Res. 14: 1685-1690

59. Neri, D., Carnemolla, B., Nissim, A., Leprini, A., Querze, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., Zardi, L., Winter, G. (1997): Targetting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform, Nat. Biotechnol. 15: 1271-1275


[Seite 92↓]

60. Nicole, P., Du, K., Couvineau, A., Laburthe, M. (1998): Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2 : Evidence for difference in the structure-function relationship, J. Pharmacol. Exp. Therap. 284: 744-750

61. Nicole, P., Lins, L., Rouyer-Fessard, C., Drouot, C., Fulcrand, P., Thomas, A., Couvineau, A., Martinez, J., Brasseur, R., Laburthe, M. (2000a): Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist, J. Biol. Chem . 275: 24003-24012

62. Nicole, P., Maoret, J.-J., Couvineau, A., Momany, F.A., Laburthe, M. (2000): Tryptophan 67 in the human VPAC1 receptor: Crucial role for VIP bindung, Biochem. Biochphys. Res. Commun. 276: 654-659

63. Olsen, J.O., Pozderac, R.V., Hinkle, G., Hill, T., O'Dorisio, T.M., Schirmer, W.J., Ellison, E.C., O'Dorisio M.S. (1995) : Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan), Semin. Nucl. Med . 25: 251-61

64. Olson, G.L., Bolin, D., Bonner, M.P., Bös, M., Cook, C.M., Fry, D.C., Graves, B.J., Hatada, M., Hill, D.E., Kahn, M., Madison, V.S., Rusiecki, V., Sarabu, R., Sepinwall, J., Vincent, G.P., Voss, M.E. (1993): Perspective: Concepts and progress in the development of peptide mimetics, J. Med. Chem. 36: 3039-3049

65. Pallela, V.R., Thakur, M.L., Chakder, S., Rattan, S. (1999): 99mTc-labeled vasoactive intestinal peptide receptor agonist: Functional studies, J. Nucl. Med. 40: 352-360

66. Poitout, V., Olson, L.K., Robertson, R.P. (1996): Insulin-secreting cell lines: classification, characteristics and potential application, Diabetes Metab. 22: 7-14

67. Raderer, M., Kurtaran, A., Leimer, M., Angelberger, P., Niederle, B., Vierhapper, H., Vorbeck, F., Hejna, M.H.L., Scheithauer, W., Pidlich, J., Virgolini, I. (2000): Value of peptide receptor scintigraphy using 123I-vasoactive intestinal peptide and 111In-DPTA-D-Phe1-Octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998, J. Clin. Oncol. 18: 1331-1336


[Seite 93↓]

68. Reubi, J. C. (1995): In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging, J. Nucl. Med. 36 : 1846-1853

69. Reubi, J. C., Waser, B., Schmassmann, A., Laissue, J. A. (1999): Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: Where are they really located?, Int. J. Cancer 81: 376-386

70. Reubi, J.-C., Läderach, U., Waser, B., Gebbers, J.-O., Robberecht, P., Laissue, J.A. (2000): Vasoactive intestinal peptide/pituitary cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin, Cancer Res. 60: 3105-3112

71. Riefke, B., Licha, K., Wemmler, W. (1997 ): Kontrastmittel für die optische Mammographie , Radiologe 37 : 749-755

72. Rosenberg, J.M. (1988): Octreotide: a synthetic analog of somatostatin, Drug. Intell. Clin. Pharm. 22: 748-754

73. Said, S. I., Mutt, V. (1970): Polypeptide with broad biological activity: Isolation from small intestine, Science 169: 1217-1218

74. Said, S.I., Dickman, K. (1998): Pro-Inflammatory and Anti-Inflammatory Peptides (Editor Said, I.S.,) 345-361, Marcel Dekker, New York

75. Scatchard, G. (1949): The attractions of proteins for small molecules and ions, Ann. N Y Acad. Sci. 51: 660-672

76. Schelté, P., Boeckler, C., Frisch, B., Schuber, F. (2000): Differential reactivity of maleimide and bromacetyl functions with thiols: Application to the preparation of liposomal diepitope constructs, Bioconjugate Chem. 11: 118-123


[Seite 94↓]

77. Sheward, W.J., Lutz, E.M., Copp, A.J., Harmar, A.J. (1998): Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo, Brain Res. Dev. Brain Res. 109: 245-253

78. Sreedharan, S.P., Patel, D.R., Huang, J.-X., Goetzl, E.J. (1993): Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor, Biochem. Biophy. Res. Commun. 193: 546-553

79. Sreedharan, S.P., Patel, D.R., Xia, M., Ichokawa, S., Goetzl, E.J. (1994): Human vasoactive intestinal peptide 1 receptors expressed by stable transfectants couple to two distinct signaling pathways, Biochem. Biophys. Res. Commun. 5: 145-152

80. Sreedharan, S.P., Huang, J.-X., Cheung, M.-C., Goetzl, E.J. (1995): Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene, Proc. Nat. Acad. Sci. USA 92: 2939-2943

81. Stepp, H., Sroka, R. & Baumgartner, R. (1998): Fluorescence endoscopy of gastrointestinal diseases: basic principles, techniques and clinical experience, Endoscopy 30: 379-386

82. Thakur, M. L., Marcus, C. S., Saeed, S., Pallela, V., Minami, C., Diggles, L., Pham, H. L., Ahdoot, R., Kalinowski, E. A. (2000): 99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans, J. Nuc. Med. 41: 107-110

83. Theriault, Y., Boulanger, Y., St-Pierre, S. (1991): Structural determination of the vasoactive intestinal peptide by two-dimensional 1H-NMR spectroscopy, Biopolymers 31: 459-464

84. Ulrich II, C.D., Holtmann, M., Miller, L.J. (1998): Secretin and vasoactive intestinal peptide receptors: Members of a unique family of G-protein coupled receptors, Gastroenterology 114: 382-397

85. Usdin, T.B., Bonner, T.I., Mezey, E. (1994): Two receptors for vasoactive intestinal polypeptide with similar specifity and complementary distributions, Endocrinology 135: 2662-2680


[Seite 95↓]

86. Van Rampelbergh, J., Poloczek, P., Francoys, I., Delporte, C., Winand, J., Robberecht, P., Waelbroeck, M. (1997): The pituitary adenylate cyclase activating polypeptide I (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cell through interaction with different G proteins, Biochim. Biophys. Acta. 1357: 249-255

87. Vertongen, P., De Clerck, P., Fourmet, J.-C., Martelli, H., Hélardot, P., Devalck, C., Peeters, T., Sariban, E., Robberecht, P. (1997a): Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues, Neuropeptides 31 : 404-413

88. Vertongen, P., Schiffmann, S.N., Gourlet, P., Robberecht, P. (1997b): Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain, Peptides 18: 1547-1554

89. Virgolini, I., Raderer, M., Kurtaran, A., Angerberger, P., Yang, Q., Radosavljevic, M., Leimer, M., Kaserer, K., Li, S.R., Kornek, G., Hübsch, P., Niederle, B., Pidlich, J., Scheithauer, W., Valent, P. (1996): 123I-Vasoactive Intestinal Peptide receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract, Med. Biol. 23: 685-692

90. Volkmer-Engert, R., Hoffmann, B., Schneider-Mergener, J. (1997): Stably attachment of the HMB-linker to continous cellulose membranes for parallel solid phase spot synthestis, Tetrahedron Lett. 38: 1029-1032

91. Wagnieres, G.A., Star, W.M., Wilson, B.C. (1998): In vivo fluorescence spectroscopy and imaging for oncological applications, Photochem. Photobiol. 68: 603-632

92. Weissleder, R., Tung, C.-H., Mahmood, U., Bogdanov, A. (1999): In vivo imaging of tumors with protease-activated near-infrared fluorescent probes, Nat. Biotechnol. 17: 375-378

93. Welton, A.F., Lad, P.M., Newby, A.C., Yamamura, H., Nicosia, S., Rodbell, M. (1977): Solubilization and separation of the glucagon receptor and adenylate cyclase in guanine nucleotide-sensitive states, J. Biol. Chem. 252: 5947-5950


[Seite 96↓]

94. Wiedenmann, B., John, M., Ahnert-Hilger, G., Riecken, E.-O. (1998): Molecular and cell biological aspects of neuroendocrine tumors of the gastroenteropancreatic system, J. Mol. Med. 76: 637-647

95. Wray, V., Nokihara, K., Naruse, S. (1998): Solution structure comparison of the VIP/PACAP family of peptides bei NMR spectroscopy, Ann. N.Y. Acad. Sci. 865: 37-44

96. Wulff, B., Knudsen, S.M., Adelhorst, K., Fahrenkrug, J. (1997): The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin, FEBS 413: 405-408

97. Xia, M., Sreedharan, S.P., Goetzl, E.J. (1996): Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals. J. Clin. Immunol. 16: 21-30

98. Xia, M., Spreedharan, S.P., Bolin, D., Gaufo, G.O., Goetzl, J. (1997): Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor, J. Pharm. Exp. Therap. 281: 629-633

99. Zia, H., Leyton, J., Casibang, M., Hau, V., Brennemann, D., Fridkin, M., Gozes, I., Moody, T.W. (2000): (N-Stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines, Life Sci. 66: 379-387


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
22.01.2004